Difference between revisions of "Biphasic hyalinizing psammomatous renal cell carcinoma"
Jump to navigation
Jump to search
(→IHC) |
|||
| Line 18: | Line 18: | ||
==IHC== | ==IHC== | ||
Features:<ref name=pmid32217839/> | Features:<ref name=pmid32217839/> | ||
*HNF-1beta +ve | *[[HNF-1beta]] +ve | ||
*PAX8 +ve | *[[PAX8]] +ve | ||
*CK7 +ve | *[[CK7]] +ve | ||
*EMA +ve. | *EMA +ve. | ||
*AMACR +ve. | *AMACR +ve. | ||
| Line 26: | Line 26: | ||
*Melan A -ve. | *Melan A -ve. | ||
*HMB-45 -ve. | *HMB-45 -ve. | ||
*GATA3 -ve. | *[[GATA3]] -ve. | ||
*Chromogranin A -ve. | *Chromogranin A -ve. | ||
*Synaptophysin -ve. | *Synaptophysin -ve. | ||
Revision as of 05:16, 13 October 2021
Biphasic hyalinizing psammomatous renal cell carcinoma, abbreviated BHP RCC, is a rare type of renal cell carcinoma with mutations in neurofibromin 2.[1]
General
- Evolving entity.
- Very rare.
- Prevalence: male > female.
Microscopic
Features:[1]
- Biphasic cytomorphology:
- Small cells.
- Large cells.
- Psammoma bodies.
DDx:
IHC
Features:[1]
- HNF-1beta +ve
- PAX8 +ve
- CK7 +ve
- EMA +ve.
- AMACR +ve.
- WT1 -ve
- Melan A -ve.
- HMB-45 -ve.
- GATA3 -ve.
- Chromogranin A -ve.
- Synaptophysin -ve.
- FH normal.
- SDHB normal.
References
- ↑ 1.0 1.1 1.2 Argani P, Reuter VE, Eble JN, Vlatkovic L, Yaskiv O, Swanson D, Dickson BC, Antonescu CR, Matoso A, Gagan J, Palsgrove DN (July 2020). "Biphasic Hyalinizing Psammomatous Renal Cell Carcinoma (BHP RCC): A Distinctive Neoplasm Associated With Somatic NF2 Mutations". Am J Surg Pathol 44 (7): 901–916. doi:10.1097/PAS.0000000000001467. PMC 7350624. PMID 32217839. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350624/.